LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
Titel:
LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
Auteur:
Bullock, A. Fakih, M. Gordon, M. Tsimberidou, A. El-Khoueiry, A. Wilky, B. Pimentel, A. Margolin, K. Mahadevan, D. Balmanoukian, A. Sanborn, R. Schwartz, G. Abou-Alfa, G. Bockorny, B. Moser, J. Sharma, S. Grossman, J. Rosenthal, K. O'Day, S. Lenz, H. Schlechter, B.